Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California. Show more
Location: 12780 El Camino Real, San Diego, CA, 92130, United States | Website: https://www.neurocrine.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare
Market Cap
12.41B
52 Wk Range
$84.23 - $157.98
Previous Close
$125.42
Open
$125.42
Volume
679,416
Day Range
$125.42 - $127.36
Enterprise Value
11.96B
Cash
943.5M
Avg Qtr Burn
N/A
Insider Ownership
1.09%
Institutional Own.
99.30%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
INGREZZA (valbenazine) Details Huntington's disease, Dyskinesia | Approved Quarterly sales | |
INGREZZA (valbenazine) Details Chorea, Huntington's disease, Dyskinesia | Approved Quarterly sales | |
CRENESSITY™ (crinecerfont) [oral solution] Details Congenital adrenal hyperplasia | Approved Quarterly sales | |
CRENESSITY™ (crinecerfont) [capsule] Details Congenital adrenal hyperplasia | Approved Quarterly sales | |
INGREZZA (valbenazine) Details Huntington's disease, Chorea | Approved Quarterly sales | |
Valbenazine Details Neurological disorder, Dyskinesia , Dyskinetic cerebral palsy | Phase 3 Data readout | |
Valbenazine Details Psychiatric disorder, Schizophrenia | Phase 3 Data readout | |
Osavampator (NBI-1065845/TAK-653) Details Major depressive disorder | Phase 3 Data readout | |
NBI-1117568 Details Schizophrenia | Phase 3 Update | |
NBI-1070770 Details Major depressive disorder | Phase 2 Data readout | |
Efmody Details Congenital adrenal hyperplasia | Phase 2 Update | |
NBI-921352 Details Focal Onset Seizures | Phase 2 Update | |
Chronocort® (Efmody) Details Adrenal Insufficiency | Phase 2 Update | |
NBI-1140675 Details Neurological disorder, Psychiatric disorder | Phase 1 Data readout | |
NBI-1117567 Details Neurological disorder, Psychiatric disorder | Phase 1 Data readout | |
NBI-1076986 Details Parkinson's disease, Dystonia (Blepharospasm) | Phase 1 Data readout | |
NBI-1117570 Details Schizophrenia | Phase 1 Data readout | |
NBI-1065890 Details Neurological disorder | Phase 1 Data readout | |
NBI-1065846 Details Major depressive disorder | Failed Discontinued | |
Luvadaxistat Details Psychiatric disorder, Schizophrenia | Failed Discontinued |